Skip to main content

Phase II multicenter study of arsenic trioxide, ascorbic acid and dexamethasone in patients with relapsed or refractory multiple myeloma

ISSN: 03906078
24Citations
Citations of this article
19Readers
Mendeley users who have this article in their library.

Abstract

Arsenic trioxide induces growth inhibition and apoptosis in multiple myeloma cell lines. Reducing glutathione by ascorbic acid may enhance the efficacy of arsenic trioxide. Here vire report the results of an international multi-center study of arsenic trioxide in combination with ascorbic acid and dexamethasone as treatment for patients with advanced multiple myeloma.

Cite

CITATION STYLE

APA

Wu, K. L., Beksac, M., Van Droogenbroeck, J., Amadori, S., Zweegman, S., & Sonneveld, P. (2006). Phase II multicenter study of arsenic trioxide, ascorbic acid and dexamethasone in patients with relapsed or refractory multiple myeloma. Haematologica, 91(12), 1722–1723.

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free